ST

Straumann Holding AGSWX Straumann Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Sep, 2024

Last price

Market cap $B

23.912

Large

Exchange

XSWX - Six Swiss Exchange

STMN.SW Stock Analysis

ST

Neutral

Based on Eyestock quantitative analysis, STMN.SW`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

73/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-16.7 %

Overvalued

Market cap $B

23.912

Dividend yield

0.61 %

Shares outstanding

159.35 B

Straumann Holding AG engages in the provision of implant, restorative, and regenerative dentistry solutions to dental professionals and laboratories. The company is headquartered in Basel, Basel-Stadt and currently employs 10,478 full-time employees. In collaboration with clinics, research institutes and universities, the Group researches and develops implants, instruments, computer-aided design/manufacturing (CAD/CAM) prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann Holding AG also offers a range of services to the dental profession worldwide, including training and education, provided in collaboration with the International Team for Implantology (ITI). Its products and services are available in a number of countries through the Group’s headquarters and through a network of subsidiaries and technology partners located in Europe, North America, the Asia/Pacific region and in Latin America, including Dental Wings Inc based in Canada and Createch Medical SL based in Spain.

View Section: Eyestock Rating